EUVIMEDEUVIMED entdecken
Crossref

Charting individualized pathways: IGF-1 and vitamin D in guiding personalized medicine for residual risk after AMI

Aneta Aleksova, Milijana Janjusevic, Maria Marketou, Antonio Paolo Beltrami, Elena Dozio, Giulia Vanin, Lorenzo Zandonà, Andrea Chicco, Daria Beltrame, Francesco Perone, Giulia Barbati, Andrea Giustina und 2 weitere

Progress in Cardiovascular Diseases · 2026

DOI: 10.1016/j.pcad.2026.04.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Progress in Cardiovascular Diseases, 2026. Verfasst von Aneta Aleksova und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy; Azienda Sanitaria Universitaria Giuliano Isontina, Cardio…. Hauptthemen laut MEDLINE: Insulin-Like Growth Factor I, Vitamin D, Myocardial Infarction, Vitamin D Deficiency. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Insulin-like growth factor-1 (IGF-1) and vitamin D are crucial for overall health. Imbalances in these markers are increasingly recognized as pivotal contributors to cardiovascular and residual risks following acute myocardial infarction (AMI). This study evaluated the prognostic value of IGF-1 and vitamin D levels for CAD severity and long-term outcomes in AMI survivors. METHODS: We included 681 AMI patients admitted to the University Hospital of Trieste between 2014 and 2023. RESULTS: Mean age was 66.3 years; 73.2% were male, and 71.9% had STEMI. The median IGF-1 level was 539 pg/ml and it was found to decline with ageing and with worsening kidney function. 56.1% of patients had hypovitaminosis D (HypoD), which was associated with higher levels of inflammation (CRP, IL-1β) and lower IGF-1 concentrations. Both low and high IGF-1 levels independently predicted severe CAD, indicating a U-shaped association. Over a median 51-month follow-up, 265 patients reached the composite endpoint and IGF-1 levels were lower in patients with events. Furthermore, continuous hazard ratio analysis revealed that IGF-1 levels below the median were linearly associated with adverse outcomes. Patients with the dual burden of low IGF-1 and HypoD exhibited higher probability of the composite endpoint. This combination independently predicted adverse outcomes (HR 1.43), alongside traditional risk factors such as age, LVEF, elevated HbA1C, CAD severity and impaired renal function. CONCLUSION: Low IGF-1 levels were associated with severe CAD and worse prognosis. This risk was further increased in patients with co-existing HypoD, thus additional studies are needed to determine how these biomarkers can be integrated into the clinical management of the patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin-Like Growth Factor IVitamin DMyocardial InfarctionVitamin D DeficiencyPrecision MedicineHumansMaleBiomarkersAgedFemaleRisk AssessmentRisk FactorsTime FactorsPrognosisMiddle AgedPredictive Value of TestsItalySeverity of Illness IndexRetrospective Studies

Stichwörter der Autor:innen

Insulin-like growth factor-1 (IGF-1)Ischemic heart diseaseMACEPersonalized medicineResidual cardiovascular riskVitamin D

Substanzen

BiomarkersInsulin-Like Growth Factor IVitamin DIGF1 protein, human

Autor:innen und Institutionen

  • Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy; Azienda Sanitaria Universitaria Giuliano Isontina, Cardiothoracovascular Department, Trieste, Italy. Electronic address: aaleks…
  • Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy; Azienda Sanitaria Universitaria Giuliano Isontina, Cardiothoracovascular Department, Trieste, Italy.
  • Cardiology Department Crete, School of Medicine, Heraklion University General Hospital, University of Crete, Crete, Greece.
  • Dipartimento di Area Medica (DAME), Istituto di Patologia Clinica, University of Udine, Udine, Italy.
  • Department of Biomedical Sciences for Health, University of Milan, Milan, Italy; Experimental Laboratory for Research on Organ Damage Biomarkers, IRCCS Istituto Auxologico Italiano, Milan, Italy.
  • Azienda Sanitaria Universitaria Giuliano Isontina, Cardiothoracovascular Department, Trieste, Italy.

Zitieren

APA

Aleksova, A., Janjusevic, M., Marketou, M., Beltrami, A. P., Dozio, E., Vanin, G., Zandonà, L., Chicco, A., Beltrame, D., Perone, F., Barbati, G., Giustina, A., Sinagra, G., & Fluca, A. L. (2026). Charting individualized pathways: IGF-1 and vitamin D in guiding personalized medicine for residual risk after AMI. Progress in Cardiovascular Diseases. https://doi.org/10.1016/j.pcad.2026.04.003

Vancouver

Aleksova A, Janjusevic M, Marketou M, Beltrami AP, Dozio E, Vanin G, et al. Charting individualized pathways: IGF-1 and vitamin D in guiding personalized medicine for residual risk after AMI. Progress in Cardiovascular Diseases. 2026. doi:10.1016/j.pcad.2026.04.003

BibTeX
@article{Aleksova2026,
  author = {Aleksova, Aneta and Janjusevic, Milijana and Marketou, Maria and Beltrami, Antonio Paolo and Dozio, Elena and Vanin, Giulia and Zandonà, Lorenzo and Chicco, Andrea and Beltrame, Daria and Perone, Francesco and Barbati, Giulia and Giustina, Andrea and Sinagra, Gianfranco and Fluca, Alessandra Lucia},
  title = {Charting individualized pathways: IGF-1 and vitamin D in guiding personalized medicine for residual risk after AMI},
  journal = {Progress in Cardiovascular Diseases},
  year = {2026},
  doi = {10.1016/j.pcad.2026.04.003}
}
Kostenlos starten →